Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

SOPHiA GENETICS SA

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTONAND ROLLE,SWITZERLAND, AUG. 5, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE SOFTWARE COMPANY AND LEADER IN DATA-DRIVEN MEDICINE, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. SECOND QUARTER 2025 FINANCIAL RESULTS REVENUE WAS $18.3 MILLION, UP 16% YEAR-OVER-YEAR GROSS MARGIN WAS 67.0% ON A REPORTED BASIS AND 74.4% ON AN ADJUSTED BASIS, UP FROM 68.2% REPORTED AND 73.2% ADJUSTED IN THE PRIOR YEAR PERIOD IFRS NET LOSS INCREASED 48% YEAR-OVER-YEAR TO $22.4 MILLION (OR 23% EXCLUDING FOREIGN EXCHANGE IMPACT); ADJUSTED EBITDA LOSS INCREASED 33% TO $11.7 MILLION; CASH BURN IMPROVED 35% TO $8.7 MILLION (OR 10% EXCLUDING FOREIGN EXCHANGE IMPACT) THE COMPANY REITERATES FULL-YEAR GUIDANCE OF REVENUE BETWEEN $72 MILLION AND $76 MILLION AND ADJUSTED EBITDA LOSS BETWEEN $35 MILLION AND $39 MILLION "WE DELIVERED ANOTHER STRONG QUARTER OF REVENUE GROWTH IN Q2 WITH 16% YEAR-OVER-YEAR GROWTH, AS NEW BUSINESS CONTINUES TO RAMP AND TRANSFORMATIVE APPLICATIONS LIKE MSK-ACCESS POWERED WITH SOPHIA DDMTM GAIN ADOPTION," SAID JURGI CAMBLONG, PHD.

SOPHIA GENETICS REPORTS SECOND QUARTER 2025 RESULTS

BOSTON AND ROLLE, SWITZERLAND , AUG. 5, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE HEALTHCARE TECHNOLOGY COMPANY AND A GLOBAL LEADER IN DATA-DRIVEN MEDICINE, TODAY ANNOUNCED AN EXPANSION OF ITS PARTNERSHIP WITH ASTRAZENECA (LSE/STO/NASDAQ: AZN). THIS NEW, MULTI-YEAR COLLABORATION WILL LEVERAGE SOPHIA GENETICS'S MULTIMODAL AI FACTORIES TO GENERATE EVIDENCE ON THE EFFICACY, VALUE, AND REAL-WORLD IMPACT OF THERAPIES FOR CERTAIN TYPES OF BREAST CANCER.

SOPHIA GENETICS EXPANDS COLLABORATION WITH ASTRAZENECA USING AI TO IMPROVE BREAST CANCER PATIENT OUTCOMES

BOSTON ANDROLLE, SWITZERLAND , JULY 22, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE SOFTWARE COMPANY AND A LEADER IN DATA-DRIVEN MEDICINE, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 BEFORE U.S. MARKETS OPEN ON TUESDAY, AUGUST 5, 2025. ON THAT DAY, SOPHIA GENETICS WILL HOST A CONFERENCE CALL TO DISCUSS ITS FINANCIAL RESULTS AS WELL AS BUSINESS OUTLOOK BEGINNING AT 8:00 A.M.

SOPHIA GENETICS TO ANNOUNCE FINANCIAL RESULTS FOR SECOND QUARTER 2025 ON AUGUST 5, 2025

BOSTON AND ROLLE, SWITZERLAND , MAY 6, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE SOFTWARE COMPANY AND LEADER IN DATA-DRIVEN MEDICINE, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. FIRST QUARTER 2025 FINANCIAL RESULTS REVENUE WAS $17.8 MILLION, UP 13% YEAR-OVER-YEAR OR 15% ON A CONSTANT CURRENCY BASIS GROSS MARGIN WAS 68.7% ON A REPORTED BASIS AND 75.7% ON AN ADJUSTED BASIS, UP FROM 65.9% AND 70.5% IN THE PRIOR YEAR PERIOD, RESPECTIVELY IFRS NET LOSS INCREASED 27% YEAR-OVER-YEAR TO $17.4 MILLION (INCLUDING A NET FOREIGN EXCHANGE P&L IMPACT OF $5.2 MILLION), AND ADJUSTED EBITDA LOSS IMPROVED 24% YEAR-OVER-YEAR TO $9.8 MILLION THE COMPANY REITERATES FULL-YEAR GUIDANCE OF REVENUE BETWEEN $72 MILLION AND $76 MILLION AND ADJUSTED EBITDA LOSS BETWEEN $35 MILLION AND $39 MILLION "WE STARTED THE YEAR STRONG WITH YEAR-OVER-YEAR REVENUE GROWTH OF 13%, OR 15% ON A CONSTANT CURRENCY BASIS, AS THE LARGE AMOUNT OF NEW BUSINESS SIGNED IN 2024 BEGINS TO RAMP," SAID JURGI CAMBLONG, PHD.

SOPHIA GENETICS REPORTS FIRST QUARTER 2025 RESULTS

BOSTON AND ROLLE, SWITZERLAND , APRIL 28, 2025 /PRNEWSWIRE/ --SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE HEALTHCARE TECHNOLOGY COMPANY AND GLOBAL LEADER IN DATA-DRIVEN MEDICINE, TODAY ANNOUNCED THE EXPANSION OF ITS ONGOING COLLABORATION WITH ASTRAZENECA (LSE/STO/NASDAQ: AZN) TO ACCELERATE THE DEPLOYMENT OF MSK-ACCESS POWERED WITH SOPHIA DDM GLOBALLY. BUILDING ON THE INITIAL COLLABORATION ANNOUNCED IN OCTOBER 2024 , THIS NEW PHASE WILL EXTEND THE TEST'S REACH TO A TOTAL OF 30 CLINICAL INSTITUTIONS WORLDWIDE IN 2025.

SOPHIA GENETICS ANNOUNCES EXPANDED COLLABORATION WITH ASTRAZENECA TO ACCELERATE LIQUID BIOPSY TESTING GLOBALLY FROM AACR

BOSTON ANDROLLE, SWITZERLAND , APRIL 22, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE SOFTWARE COMPANY AND A LEADER IN DATA-DRIVEN MEDICINE, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE FIRST QUARTER 2025 BEFORE U.S. MARKETS OPEN ON TUESDAY, MAY 6, 2025. ON THAT DAY, SOPHIA GENETICS WILL HOST A CONFERENCE CALL TO DISCUSS ITS FINANCIAL RESULTS AS WELL AS BUSINESS OUTLOOK BEGINNING AT 8:00 A.M.

SOPHIA GENETICS TO ANNOUNCE FINANCIAL RESULTS FOR FIRST QUARTER 2025 ON MAY 6, 2025

THE PARTNERSHIP INTEGRATES ADVANCED AI-DRIVEN ANALYTICS AND CLINICAL TRIAL SOLUTIONS, EMPOWERING BIOPHARMA COMPANIES TO ACCELERATE DRUG DEVELOPMENT AND DELIVER TARGETED THERAPIES FASTER. BETHESDA, MD.

PRECISION FOR MEDICINE PARTNERS WITH SOPHIA GENETICS TO EXPAND BIOPHARMA SERVICES WITH THE SOPHIA DDM PLATFORM AND ITS LIQUID BIOPSY CAPABILITIES

BOSTON, MA AND ROLLE, SWITZERLAND , MARCH 18, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE SOFTWARE COMPANY AND LEADER IN DATA-DRIVEN MEDICINE, HAS REACHED A HISTORIC MILESTONE: MORE THAN TWO MILLION PATIENTS GENOMIC PROFILES ANALYZED ON THE AI-POWERED ANALYTICS PLATFORM SOPHIA DDM. THIS ACHIEVEMENT SOLIDIFIES SOPHIA GENETICS AS THE GOLD-STANDARD PROVIDER OF ACTIONABLE INSIGHTS FOR PATIENT CARE, APPLYING AI CAPABILITIES SHAPED BY AN UNMATCHED DATASET OF DIVERSE, REAL-WORLD PATIENT DATA.

SOPHIA GENETICS ANNOUNCES TWO MILLION PATIENT CASES ANALYZED, MARKING A NEW MILESTONE FOR DATA-DRIVEN MEDICINE AT NVIDIA GTC

BOSTON AND ROLLE, SWITZERLAND , MARCH 4, 2025 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A CLOUD-NATIVE SOFTWARE COMPANY AND LEADER IN DATA-DRIVEN MEDICINE, TODAY REPORTED FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR ENDED DECEMBER 31, 2024. FOURTH QUARTER 2024 FINANCIAL HIGHLIGHTS REVENUE WAS $17.7 MILLION, UP 4% YEAR-OVER-YEAR OR 6% ON A CONSTANT CURRENCY BASIS EXCLUDING COVID-19-RELATED REVENUE GROSS MARGIN WAS 68.2% ON A REPORTED BASIS AND 74.2% ON AN ADJUSTED BASIS, COMPARED TO 69.8% AND 73.4% IN THE PRIOR YEAR PERIOD, RESPECTIVELY OPERATING LOSS WAS $17.4 MILLION ON A REPORTED BASIS AND $10.2 MILLION ON AN ADJUSTED BASIS, REPRESENTING YEAR-OVER-YEAR IMPROVEMENTS OF 8% AND 23%, RESPECTIVELY FULL YEAR 2024 FINANCIAL HIGHLIGHTS REVENUE WAS $65.2 MILLION, UP 4% YEAR-OVER-YEAR OR 5% ON A CONSTANT CURRENCY BASIS EXCLUDING COVID-19-RELATED REVENUE GROSS MARGIN WAS 67.4% ON A REPORTED BASIS AND 72.8% ON AN ADJUSTED BASIS, COMPARED TO 68.8% AND 72.2% IN THE PRIOR YEAR PERIOD, RESPECTIVELY OPERATING LOSS WAS $66.6 MILLION ON A REPORTED BASIS AND $44.8 MILLION ON AN ADJUSTED BASIS, REPRESENTING YEAR-OVER-YEAR IMPROVEMENTS OF 11% AND 20%, RESPECTIVELY "WE CONTINUED DRIVING WIDESPREAD ADOPTION OF SOPHIA DDMIN 2024, ACHIEVING A RECORD NUMBER OF ANALYSES, MAJOR NEW CUSTOMERS WINS, AND HEALTHY VOLUME GROWTH DURING THE YEAR, DESPITE BIOPHARMA HEADWINDS WHICH IMPACTED OVERALL PERFORMANCE AND RESULTED IN SOFTER REVENUE GROWTH THAN WE WOULD HAVE LIKED," SAID JURGI CAMBLONG, PHD.

SOPHIA GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

SOPHIA GENETICS ENABLES INSTITUTIONS ACROSS THE GLOBE TO LAUNCH WORLD-CLASS ONCOLOGY TESTING BOSTON, MA ANDROLLE, SWITZERLAND, FEB. 24, 2025 /PRNEWSWIRE/ --SOPHIA GENETICS (NASDAQ: SOPH), A PIONEER IN AI HEALTHCARE TECHNOLOGY AND A LEADER IN DATA-DRIVEN MEDICINE, ANNOUNCED A NEW MILESTONE IN THE GLOBAL ADOPTION OF ITS GROUNDBREAKING CANCER TESTING APPLICATIONS MSK-ACCESS POWERED WITH SOPHIA DDM AND MSK-IMPACT POWERED WITH SOPHIA DDM. THIRTY-SEVEN PROMINENT INSTITUTIONS, INCLUDING TOP RESEARCHERS AND KEY OPINION LEADERS WORLDWIDE, HAVE ALREADY ADOPTED THE RECENTLY LAUNCHED LIQUID BIOPSY AND SOLID TUMOR APPLICATIONS.

SOPHiA GENETICS SA

SOPH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SOPHiA GENETICS SA

SOPH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SOPH